Combined MEK/MDM2 Inhibition Demonstrates Antitumor Efficacy in TP53 Wild-Type Thyroid and Colorectal Cancers with MAPK Alterations

Researchers evaluated combination therapy with MEK inhibitor selumetinib and MDM2 inhibitor KRT-232 in TP53 wild-type and mitogen-activated protein kinase (MAPK) altered colon and thyroid cancer models.